


PHARMACEUTICAL 2018

SCYNEXIS INC Rank 199 of 349







PHARMACEUTICAL 2018

SCYNEXIS INC Rank 199 of 349



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 139% points. The greatest weakness of SCYNEXIS INC is the variable Research and Development, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is -222%, being 55% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	44,960
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,144
Liabilities, Non-Current	10,303
Other Assets	890
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,993
Other Net Income	1,260
Property and Equipment	0
Research and Development	18,326
Revenues	257
Selling, General and Administrative Expense	8,251

Output Variable	Value in 1000 USD
Assets	45,850
Liabilities	24,440
Expenses	26,577
Stockholders Equity	21,410
Net Income	-25,060
Comprehensive Net Income	-25,060
Economic Capital Ratio	-222%